rs151007312
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS2
The NM_013266.4(CTNNA3):c.1402G>A(p.Ala468Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000645 in 1,612,448 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_013266.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CTNNA3 | NM_013266.4 | c.1402G>A | p.Ala468Thr | missense_variant | 11/18 | ENST00000433211.7 | NP_037398.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CTNNA3 | ENST00000433211.7 | c.1402G>A | p.Ala468Thr | missense_variant | 11/18 | 1 | NM_013266.4 | ENSP00000389714 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151936Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 249894Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135046
GnomAD4 exome AF: 0.0000692 AC: 101AN: 1460512Hom.: 0 Cov.: 30 AF XY: 0.0000729 AC XY: 53AN XY: 726600
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151936Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74190
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 03, 2023 | The p.A468T variant (also known as c.1402G>A), located in coding exon 10 of the CTNNA3 gene, results from a G to A substitution at nucleotide position 1402. The alanine at codon 468 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Arrhythmogenic right ventricular dysplasia 13 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 05, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 568270). This variant has not been reported in the literature in individuals affected with CTNNA3-related conditions. This variant is present in population databases (rs151007312, gnomAD 0.004%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 468 of the CTNNA3 protein (p.Ala468Thr). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at